|
 |
AgeneraseThis page contains recent news articles, when available, and an overview of Agenerase but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Agenerase (when available) Amprenavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Amprenavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. For the treatment of HIV-1 infection in combination with other antiretroviral agents Mechanism Of Action: Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. News Articles on Amprenavir MHT All-Star Roger Tung: Life saver - Nov 3, 2009 Tung co-invented two key HIV protease inhibitors, marketed as Agenerase and Lexiva, which he calls two of his most important achievements. ... Mass High Tech Vertex Pharmaceuticals Reports Third Quarter 2009 Financial Results and ... - Oct 26, 2009 Note 6: In the first quarter of 2008, the Company recognized royalty revenues based on actual and estimated net sales of Lexiva/Telzir and Agenerase by ... Reuters Viagra rivals add hours of hope for men - $1.15 per PILL - Jun 30, 2009 ...blood thinners, cimetidine, certain antibiotics, doxazosin, prazosin, Terazosin, HIV medicines such as amprenavir (Agenerase), tipranavir (Aptivus), Toute la Poésie New HIV Drug Company Formed By Glaxo And Pfizer - Apr 17, 2009 The full portfolio of 11 drugs comprises: Agenerase, Combivir, Epivir/3TC, Epzicom/Kivexa, Lexiva/Telzir, Rescriptor, Retrovir/AZT, Selzentry/Celsentri, Medical News Today Vertex Pharmaceuticals Reviews First Quarter Business Progress and ... - Apr 16, 2009 Note 6: In the first quarter of 2008, the Company recognized royalty revenues based on actual and estimated net sales of Lexiva/Telzir and Agenerase by Trading Markets (press release) COMUNICADO: Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice ... - Aug 5, 2008 KALETRA should not be given once-daily in combination with Sustiva(R) (efavirenz), Viramune(R) (nevirapine), Agenerase(R) (amprenavir), fosamprenavir, Europa Press (Comunicados de prensa), Vertex Pharmaceuticals Highlights Telaprevir Progress and Reports ... - Jul 31, 2008 ...to future royalties of the HIV protease inhibitors Lexiva/Telzir and Agenerase under the Company's 1993 license agreement with GlaxoSmithKline plc. MarketWatch Winners & Losers Health Winners & Losers: Vertex - Jun 3, 2008 Vertex Pharmaceuticals VRTX said it sold the rights to future royalties in HIV drugs Lexiva and Agenerase for a one-time cash payment of $160 million. TheStreet.com Drug stocks edge higher; Genentech retreats - Jun 3, 2008 The biotech group said it has sold its rights to future royalties from the HIV drugs Lexiva and Agenerase for $160 million. Both drugs are marketed by MarketWatch GSK pays£80m for royalty rights to HIV drugs - Jun 5, 2008 The drugmaker has paid $160 million (£80 million) for the future royalties to Lexiva and Agenerase. Lexiva is an HIV protease inhibitor which was discovered Hays Pharma, Vertex Pharmaceuticals "positive," target price raised - update - Jun 7, 2008 ...analysts mention that the company has sold the rights to future royalties for its HIV protease inhibitor drugs, Lexiva and Agenerase, for $160 million. newratings.com, GSK pays Epix£2.8m - Jun 6, 2008 Earlier this week, GSK announced that it has paid Vertex Pharmaceuticals $160 million for the future royalty rights to two HIV drugs, Lexiva and Agenerase. Hays Pharma, Vertex Gambles On Telaprevir - Jun 5, 2008 ...it received $48.0 million from GlaxoSmithKline and made out $13.9 million to a third party associated with the licensing of Lexiva and Agenerase, Forbes, Vertex Pharmaceuticals Announces Webcast of its Presentation at ... - Jun 6, 2008 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Goldman Sachs 29th Annual Global WELT ONLINE, Alternative Financing Strategies not a Cure-All for the Industry - Jun 19, 2008 ...based Vertex Pharmaceuticals Inc. sold an interest in its royalties for Lexiva (fosamprenavir calcium) and Agenerase (amprenavir) to an unnamed buyer, TMCnet GSK buys rights to two Vertex HIV drugs for $160M - Jun 5, 2008 GlaxoSmithKline has purchased rights to future royalties on Lexiva and Agenerase, Vertex Pharmaceuticals' HIV drugs, for $160 million. SmartBrief, GSK buys rights to two Vertex HIV drugs for $160M - Jun 4, 2008 GlaxoSmithKline has purchased rights to future royalties on Lexiva and Agenerase, Vertex Pharmaceuticals' HIV drugs, for $160 million. SmartBrief, Market Report -- In Play (VRTX) - Jun 3, 2008 Vertex Pharm sells HIV product royalty stream for $160 mln Co announced that it has sold its rights to future royalties in Lexiva and Agenerase under its MSN Money Vertex sells HIV drug royalties; AstraZeneca's Iressa may treat ... - Jun 4, 2008 By christe > ImClone's Erbitux shows promise for advanced lung and colorectal cancers, but not at expense of current leading drug, Genentech's Avastin. FiercePharma, Brand Names/Synonyms: Agenerase is also known by the following brand names and/or synonyms: 141w94, Kvx-478, Agenerase, Prozei,; Agenerase; Amprenavir; Lexiva; VX-478 Drug Category: Agenerase is categorized under the following by the FDA: Anti-HIV Agents; Antibiotics; Anti-HIV Agents; ATC:J05AE05; ATC:J05AE07 Dosage Forms: CAPSULE Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: tetrahydrofuran-3-yl[3-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-benzyl-2-hydroxy-propyl]aminomethanoate |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
